The dysfunction of cytosolic HSP90 in inhibitor-treated tumor cells may result in the inactivation and degradation of several cancer-promoting proteins, thus impairing the viability and adaptiveness of target tumor cells (see Figure 2 and [49,50,51]). Here, HSP90AB1 is linked to neoplasm.